Zhou Huili, Xu Wei, Wu Guolan, Wu Lihua, Shentu Jianzhong, Pan Zhengfei, Hu Shuai, Liu Yang
Int J Clin Pharmacol Ther. 2016 Nov;54(11):904-913. doi: 10.5414/CP202603.
Recently a formulation of intravenous (IV) ibuprofen was developed in China for management of mild to moderate pain in patients who could not take oral medications or where intravenous administration was preferable. The aim of this study was to evaluate the pharmacokinetic properties and tolerability of single and multiple doses of ibuprofen injection in healthy Chinese volunteers.
This open-label, single- and multiple-dose study was conducted in healthy Chinese volunteers. In the single-dose phase, subjects were randomized to receive a single dose of ibuprofen injection 0.2, 0.4, or 0.8 g administered as a 30-minute IV infusion with a 1-week washout between periods. Blood samples were collected at regular intervals from 0 to 12.5 hours after drug administration and were analyzed using a validated LC-MS/MS method. In the multiple-dose phase, subjects received 0.4 g ibuprofen every 6 hours for 9 doses. Blood samples were obtained before the 7, 8, and 9 administration to determine the C at steady state; on the 9 intravenous administration, blood samples were also collected for 12.5 hours after drug administration. Pharmacokinetic parameters were estimated using a noncompartmental model. Tolerability was determined using clinical evaluation and monitoring of adverse events (AEs).
A total of 12 healthy male (n = 6) and female (n = 6) Chinese volunteers were enrolled and completed the trial. After IV administration of single dose, the mean (SD) C value increased from 35.77 (6.98) to 117.12 (19.78) µg/mL, and the mean (SD) AUC value increased from 67.63 (10.30) to 230.50 (33.55) µg×h/mL in the range of 0.2-g to 0.8-g dose. The terminal half-life in plasma was ~ 2.0 hours. After IV administration of 9 doses of ibuprofen 400 mg every 6 hours, the mean (SD) C was 66.49 (8.49) µg/mL, the AUC was 135.65 (26.91) µg×h/mL, the t was 2.14 (0.34) hours, the Cl/F was 3.34 (0.68) L/h, and the Vz/F was 10.32 (2.69) L, which were comparable with those after single dosing. The accumulation index was 1.17 (0.06), and the fluctuation was 304.0 (57.7) %. Results of the t-tests of C and AUC found no significant differences between the male and female groups. No serious AEs were reported, and there were no discontinuations due to AEs.
CONCLUSION: The pharmacokinetics of ibuprofen exhibited dose-related kinetics from the 0.2- to the 0.8-g dose. After multiple doses, the pharmacokinetic parameters of ibuprofen were consistent with those after single doses. There was no accumulation in ibuprofen exposure in healthy Chinese between multiple doses and single dose. At the doses studied, ibuprofen appeared to be well tolerated in these healthy volunteers. .
最近中国研发了一种静脉注射用布洛芬制剂,用于治疗无法口服药物或更适合静脉给药的患者的轻至中度疼痛。本研究的目的是评估单剂量和多剂量布洛芬注射液在健康中国志愿者中的药代动力学特性和耐受性。
本开放标签的单剂量和多剂量研究在健康中国志愿者中进行。在单剂量阶段,受试者被随机分配接受0.2、0.4或0.8 g单剂量布洛芬注射液,通过30分钟静脉输注给药,各阶段之间有1周的洗脱期。在给药后0至12.5小时定期采集血样,并使用经过验证的液相色谱-串联质谱法(LC-MS/MS)进行分析。在多剂量阶段,受试者每6小时接受0.4 g布洛芬,共9剂。在第7、8和9次给药前采集血样以确定稳态下的C;在第9次静脉给药时,给药后还采集12.5小时的血样。使用非房室模型估计药代动力学参数。通过临床评估和不良事件(AE)监测确定耐受性。
共有12名健康中国志愿者(男性6名,女性6名)入组并完成试验。静脉注射单剂量后,在0.2 g至0.8 g剂量范围内,平均(标准差)C值从35.77(6.98)μg/mL增加到117.12(19.78)μg/mL,平均(标准差)AUC值从67.63(10.30)μg×h/mL增加到230.50(33.55)μg×h/mL。血浆中的末端半衰期约为2.0小时。每6小时静脉注射9剂400 mg布洛芬后,平均(标准差)C为66.49(8.49)μg/mL,AUC为135.65(26.91)μg×h/mL,t为2.14(0.34)小时,Cl/F为3.34(0.68)L/h,Vz/F为10.32(2.69)L,与单剂量给药后的结果相当。蓄积指数为1.17(0.06),波动为304.0(57.7)%。C和AUC的t检验结果显示男性和女性组之间无显著差异。未报告严重不良事件,也没有因不良事件而停药的情况。
布洛芬在0.2 g至0.8 g剂量范围内呈现出与剂量相关的药代动力学特征。多剂量给药后,布洛芬的药代动力学参数与单剂量给药后一致。在健康中国人群中,多剂量和单剂量布洛芬的暴露量无蓄积现象。在所研究的剂量下,布洛芬在这些健康志愿者中似乎耐受性良好。